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Abstract
Using plasma from patients infected or previously infected with Leishmania donovanii, we isolated a L. donovanii cDNA
clone with similarity to the proteasome a-type subunit from humans and other eukaryotes. The cDNA clone, designated
LePa, was DNA sequenced and Northern blot analysis of L. donovanii poly(A)mRNA indicated the isolation of a full
length cDNA clone with a transcript size of 1.9 kb. The expressed recombinant LePa fusion protein induced proliferation of
peripheral blood mononuclear cells in one out of seven patients who had suffered from visceral leishmaniasis. Plasma from
16 out of 25 patients with visceral leishmaniasis and four out of 18 patients with cutaneous leishmaniasis contained IgG
antibodies which reacted with the purified LePa fusion protein as evaluated in an ELISA. The LePa DNA sequence was
inserted into an eukaryotic expression vector and Balb/c mice were vaccinated. DNA vaccination of Balb/c mice with LePa
generated an initial significant reduction in lesion size after challenge. ß 2000 Elsevier Science B.V. All rights reserved.
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1. Introduction
The leishmaniases are a group of parasitic diseases
caused by Leishmania species. Depending largely on
the species of parasite and the immune response of
the host, the disease spectrum ranges from self-heal-
ing cutaneous leishmaniasis to fatal visceral leishma-
niasis or kala azar.
The immune mechanisms operating during disease
and cure of leishmaniasis have been extensively
studied both in animal models and in human infec-
tion. T-cells play an important role in the devel-
opment of immunity and cure [1]. The humoral
response during visceral leishmaniasis consists pri-
marily of an unspeci¢c hyperinduction of IgM- and
IgG-type antibodies, but a multitude of speci¢c anti-
bodies are induced against a variety of Leishmania
promastigote and amastigote antigens [2^6].
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Several Leishmania antigens activate T-cells from
individuals who have recovered from leishmaniasis,
indicating that T-cell clones recognizing epitopes on
these proteins are expanded during natural infection
[7^9]. These ¢ndings have supported the candidature
of the antigens in vaccine development. A common
feature of these antigens is that natural infection not
only induces a T-cell response, but also activates
speci¢c B-cells, since speci¢c IgG can be detected in
patient plasma both in the acute phase before treat-
ment and during convalescence [8].
In the search for antigens which can induce pro-
tective immune responses during Leishmania infec-
tion, we used a pre-selected high-titred pool of anti-
bodies from visceral leishmaniasis patients with an
ongoing or cured infection to select immunological
relevant antigens from an amastigote Leishmania do-
novanii cDNA library. In this study, we report the
cloning, expression and immunological properties of
an antigen which has similarity to the human 20S
proteasome a-type subunit. Its potential as a DNA
vaccine candidate is also evaluated.
2. Materials and methods
2.1. Parasites
L. donovanii (strain Ldd MHOM/SD/00/1S-2D,
clone Ldd 1SC12, abbreviated Ld2d) was kindly do-
nated by Dr Dennis Dwyer (NIH, MD, USA). A
Ld2d amastigote culture was used for cDNA library
construction and production of antigens. Leishmania
major (MHOM/IL/67/LRC-L437) was used for DNA
vaccine experiments. L. donovanii Ld2d amastigotes
were cultured as described by [10] whereas L. dono-
vanii and L. major promastigotes were cultured at
26‡C in RPMI 1640 supplemented with 10% fetal
calf serum, 10 mM HEPES, 20 IU/ml of penicillin
and 20 mM streptomycin.
2.2. Donors and separation of blood samples
Peripheral blood was collected by venipuncture
into heparinized vacutainers (Becton Dickinson)
and peripheral blood mononuclear cells (PBMC)
and plasma were isolated after Lymphoprep (Nye-
gaard, Oslo, Norway) density gradient centrifugation
and cryopreserved as described previously [11]. The
donors were (1) Sudanese patients with parasitolog-
ically con¢rmed visceral leishmaniasis caused by
L. donovanii and patients who had been treated for
visceral leishmaniasis [12], (2) Sudanese individuals
with active or healed cutaneous leishmaniasis caused
by L. major [13] or donors with healed cutaneous
leishmaniasis [14], (3) Sudanese control donors
from an area not endemic for leishmaniasis [15], (4)
Sudanese donors with malaria [16], (5) Danish con-
trol donors without known exposure to Leishmania.
2.3. Leishmania donovanii soluble antigens
Promastigotes and amastigotes were sonicated for
use in PBMC and ELISA as described previously
[17].
2.4. Selection of plasma for antibody screening
Plasma from donors exposed to Leishmania were
tested in ELISA measuring antibodies against L. do-
novanii sonicates from promastigotes or amastigotes,
respectively. The assays were performed as described
earlier [17]. Plasma from 13 patients with visceral
leishmaniasis and ¢ve individuals cured from visceral
leishmaniasis was selected, pooled and stored at 4‡C
until further use.
2.5. Construction and screening of amastigote cDNA
library
Total RNA was isolated from axenic amastigotes
by the method described in [18], utilizing the single
step acid guanidinium thiocyanate procedure. Poly-
(A)mRNA was isolated by loading total RNA onto
an oligo(dT) column according to the protocol pro-
vided by the manufacturer (Life Technologies). The
amastigote cDNA library was constructed in the
VZAP Express vector system according to the man-
ual provided by the manufacturer (Stratagene).
Standard protocols [19] and protocols supplied by
the manufacturer (Stratagene) were used for screen-
ing the amastigote cDNA library. The ¢lters were
probed with the absorbed antibody solution diluted
1/1000 in blocking bu¡er and processed as described
for Western blots. Antibody-reactive cDNA clones
appearing on both set of ¢lters were selected and
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then in vivo excised from the VZAP Express vector
to form the pBK-CMV phagemid.
2.6. Northern blot analysis
Amastigote and promastigote poly(A)mRNA
were puri¢ed as described above. Three Wg of pro-
mastigote poly(A)mRNA and 0.5 Wg of amastigote
poly(A)mRNA were separated in a standard dena-
turing MOPS-formaldehyde agarose gel [19]. The
DNA probe was generated by PCR, amplifying a
DNA fragment positioned in the open reading frame
of the cloned cDNA and subsequently puri¢ed by
Qiaquick (Qiagen). Labelling of the probe with
dCTP ([K-32P]dCTP, 9.25 MBq, Amersham) was
done using the Megaprime system (Amersham) fol-
lowing the manufacturer’s protocol. The blot was
processed as described by [19].
2.7. Subcloning of LePa into pGEX-4T3 and pcDNA
3.1 vectors and puri¢cation of fusion protein
To obtain fusion protein for immunological as-
says, the cDNA insert from the isolated pBK-CMV
phagemid was subcloned into the GST fusion protein
vector pGEX-4T3 (Pharmacia). The plasmid was
subsequently transformed into Escherichia coli BL-
21 cells (Pharmacia) for high level fusion protein ex-
pression. Induction and puri¢cation was done as de-
scribed in [20]. pGEX-4T3 vector without insert was
treated as described above and the eluate from the
column was used as a control in the PBMC assay
(see below). In order to ligate LePa cDNA into the
pcDNA vector for immunization of mice, the LePa
cDNA insert was PCR ampli¢ed using primers con-
taining restriction sites. The pcDNA vector and PCR
generated insert were ligated after digestion with re-
striction enzymes.
2.8. SDS-PAGE and Western blotting
All SDS-PAGE mini-gels for monitoring induc-
tion, solubility and puri¢cation of fusion proteins
for Western blots were performed on Novex mini-
gel electrophoresis equipment (Xcell II, Novex) using
standard Laemmli bu¡ers [21]. After electrophoresis,
SDS-PAGE gels were incubated 10 min in transfer
bu¡er and processed as described by the manufac-
turer (Novex). Blotting of proteins onto nitrocellu-
lose membranes was performed for 2 h at 30 V
constant voltage. After blotting, nitrocellulose mem-
branes were washed and subsequently blocked and
processed as described in [22]. Western blots were
incubated with a promastigote antigen-absorbed se-
rum pool from the original selected screening donors
and controls or mice sera. Blots were then washed
and incubated for 1 h at room temperature with the
relevant IgG alkaline phosphatase-conjugated anti-
body. Development of the blot was done using
standard techniques.
2.9. PBMC assays
On the day of assay PBMC were thawed, washed
and counted [11]. Wells of round-bottomed micro-
titre plates received 0.66U106 cells/ml of PBMC in
150 Wl of RPMI 1640 supplemented with 15% heat-
inactivated pooled normal human serum, 58.4 Wg/ml
L-glutamine, 20 IU/ml penicillin, and 20 Wg/ml strep-
tomycin (Gibco, Paisley, UK). Twenty Wl of antigen
solution or 20 Wl of medium was added to test cul-
tures and control cultures, respectively. The recombi-
nant LePa and control GST solutions were diluted in
RPMI 1640 and used at a ¢nal concentration of 1^20
Wg/ml. A sonicate of L. donovanii promastigotes was
used at a ¢nal protein concentration of 7 Wg/ml. Pu-
ri¢ed protein derivative of tuberculin (PPD; Statens
Seruminstitut, Copenhagen, Denmark) was used at a
¢nal concentration of 12 Wg/ml. After incubation for
6 days at 37‡C in a humidi¢ed atmosphere contain-
ing 5% CO2 the cells were pulsed with 20 Wl/well of
[3H]thymidine (New England Nuclear, Boston, MA,
USA) (1.85 Mbq/well). The cells were harvested onto
glass ¢bre ¢lters on day 7 and the incorporation of
[3H]thymidine into DNA was determined by a Ma-
trix counter (Packard, Greve, Denmark).
2.10. rLePa ELISA
The rLePa and GST were expressed in E. coli,
puri¢ed as described above and the ELISA proce-
dure described in [17] was essentially followed.
2.11. Immunization and DNA vaccine experiments
For generation of antibodies for use in Western
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blots four Balb/c mice were immunized intradermally
in the tail with 80 Wg of pcDNA-LePa in 50 Wl of
saline a total of 3 times with 2 week intervals. Mice
were bled 2 weeks after the last immunization. For
DNA vaccination groups of six female Balb/c mice
were injected with pcDNA 3.1 (control plasmid) or
pcDNA 3.1 containing the LePa cDNA insert. Each
mouse received 50 Wg of plasmid in 50 Wl saline in
each tibialis anterior muscle (100 Wg total). Mice
were boosted with the same amount of DNA at
3 weeks and 6 weeks post priming. Mice were chal-
lenged with 106 L. major promastigotes in the rump
at 2 weeks after the last immunization. The lesion
size was measured weekly using a calliper. Parasite
loads in the lesions and in the spleen were deter-
mined by microscopy and by a limiting dilution assay
[23], respectively.
2.12. DNA sequencing and analysis
DNA sequencing was performed using an auto-
mated ABI 377 sequencing system and the Ampli-
Cycle Sequencing Kit (Perkin Elmer). DNA sequence
analysis was performed using DNAstar computer
software (Madison, WI, USA), while sequence ho-
mology analysis was performed by the programmes
o¡ered in the Program Manual for the Wisconsin
Package, Version 8, September 1994, Genetics Com-
puter Group (Madison, WI, USA) available at Bio-
base (Aarhus, Denmark).
2.13. Calculations and statistical analysis
PBMC and ELISA tests were done in duplicate.
In the ELISA a positive plasma pool was used
as a reference. The results were calculated as
arbitrary ELISA units (ODsample3ODbackground)/
(ODreference plasma3ODbackground)U100% to account
for day-to-day variation. The cuto¡ level was deter-
mined as the mean ELISA units of the plasma from
non-endemic controls plus 2 S.D.s. Because of the
skewed distributions of the data the Kruskal-Wallis
one way analysis of variance on ranks was applied
for multiple comparisons and if signi¢cant di¡eren-
ces were found, Dunn’s method was used to identify
signi¢cant di¡erences between groups. All P values
less than 0.05 were considered signi¢cant. All calcu-
lations were performed using SigmaStat version 2
software (Jandel Scienti¢c). In the DNA vaccination
experiment, a two way repeated measures analysis of
variance on two factors was used to analyse the data.
All P values less than 0.05 were considered signi¢-
cant. All calculations were performed using Sigma-
Stat version 2 software (Jandel Scienti¢c).
In the PBMC assay, the response to an antigen
was expressed as the increment in kilocounts per
minute (kCPM). A positive response was de¢ned as
stimulatory index (SI)s 2.0 and increment of s 0.3
kCPM.
3. Results
3.1. Screening of cDNA library
Plasma from 18 donors with active or cured vis-
ceral leishmaniasis was used to screen the L. donova-
nii amastigote cDNA library. From a total of 2U106
recombinant clones, 54 clones were isolated and in-
sert size evaluated by PCR. A number of clones were
selected and pBK-CMV phagemids were generated
by in vivo excision. One clone, which reacted
strongly with the visceral leishmaniasis plasma
pool, was selected for further study.
3.2. DNA sequence analysis
The sequence of the cloned cDNA insert is shown
in Fig. 1. The sequence contained a 1821 bp insert
with an open reading frame of 753 bp found in the
5P end of the sequence. A putative methionine start
codon was identi¢ed at nucleotide position 69 in the
open reading frame. No additional start codons
(ATG) were found upstream from the putative start
codon, and the nucleotide at position 33 relative to
the start codon was an A as predicted for 95% of
eukaryotic mRNA sequences [24]. However, the nu-
cleotide at position +4 was di¡erent from the ex-
pected purine base (G). The insert showed a poly(A)
sequence at the 3P terminus indicating the poly-
(A)mRNA origin. However, a poly(A) adenylation
signal sequence (AATAAA) was not identi¢ed. The
translated open reading frame indicated expression
of a putative protein with a molecular mass of ap-
prox. 27.2 kDa (250 amino acids) and a calculated pI
of 7.7. The open reading frame showed a 49.2%
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Fig. 1. DNA and deduced amino acid sequence of LePa. The deduced coding region (residues 1^250) is indicated by single-letter ami-
no acid abbreviations together with uppercase base designations. Stop codon is indicated by an asterisk.
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DNA sequence similarity to the human 20S protea-
some a-type subunit [25], a multi-substrate catalytic
proteinase complex [26,27]. A Swiss-Prot protein da-
tabase search showed 45.7% identity with the a-type
subunit at the protein level. Fig. 2 shows the protein
sequence comparison between the Leishmania se-
quence and human 20S proteasome a-type subunit.
3.3. Northern blot analysis
A labelled nucleotide probe spanning the ¢rst 712
nucleotides of the open reading frame hybridized to a
transcript of approx. 1.9 kb from both the amasti-
gote and promastigote stage (Fig. 3). The highest
expression of the transcript, as indicated by the in-
tensity of the signal, was seen in the promastigote
stage as expected due to the higher concentration
of loaded promastigote poly(A)mRNA.
3.4. GST fusion protein reactivity (Western blot,
PBMC and ELISA)
The cDNA sequence encompassing the open read-
ing frame was inserted into pGEX and recombinant
LePa (rLePa) was produced. In a Western blot anal-
ysis using crude E. coli induced and non-induced
lysate, anti-GST antibodies reacted with GST alone
and with rLePa (Fig. 4A, lanes 2 and 4). Plasma
from visceral leishmaniasis patients reacted with rLe-
Pa but not with GST (Fig. 4B, lanes 2 and 4). Plasma
from Danish controls did not react with GST or
rLePa (Fig. 4C). rLePa was then used in prolifera-
tion assays and ELISA.
The rLePa fusion protein induced proliferation in
PBMC cultures from one of seven individuals previ-
ously infected with L. donovanii (Table 1). PBMC
isolates from four individuals previously infected
with L. major or four Danish controls did not re-
spond to rLePa (data not shown). rLePa was used
as solid phase ligand in an ELISA (Fig. 5). Antibod-
ies to the fusion protein were detected in plasma
from 16 of 25 visceral leishmaniasis patients and in
Fig. 2. Protein sequence comparison between LePa (residues 1^250) and human proteasome a-subunit (Hpas; residues 1^246 [25]),
showing 45.6% identity. Identical residues are shown with dark background.
Fig. 3. Northern blot analysis of LePa. Three Wg of poly-
(A)mRNA from promastigotes (P) and 0.5 Wg of poly-
(A)mRNA from amastigotes (A) were separated on a formal-
dehyde-agarose gel. After transfer onto nitrocellulose, the blot
was hybridized with a probe encompassing the open reading
frame of LePa. The size of the transcript is indicated on the
right.
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four of 18 patients with cutaneous leishmaniasis.
Plasma from Sudanese controls did not show any
antibody reactivity to rLePa. A signi¢cant di¡erence
was found between the three patient groups
(P6 0.05).
3.5. DNA vaccination
The LePa open reading frame was ligated into the
pcDNA3.1 eukaryotic expression vector. In order to
verify the integrity of the construct and its ability to
express protein, four Balb/c mice were immunized
3 times intradermally in the tail. The antibodies
were tested in a Western blot and were shown to
react with the rLePa, whereas serum from mice im-
munized with empty pcDNA3.1 did not react with
the rLePa (Fig. 6). To test the e⁄cacy of DNA vac-
cination with LePa DNA, groups of six mice were
vaccinated 3 times intramuscularly and challenged
with 106 L. major promastigotes 2 weeks after the
last DNA vaccination. DNA plasmid without insert
was used as a control. As shown in Fig. 7, DNA
vaccination of mice with pcDNA-LePa reduced the
lesion size up to 7 weeks post infection as compared
to the controls. However, at week 9 post infection,
the lesion size of pcDNA-LePa vaccinated mice
was identical to that of the controls. When data
Fig. 4. Western blot analysis of antibody reactivity against bacterial lysates containing GST or LePa. (A) Anti-GST antibodies; (B)
plasma from visceral leishmaniasis patients ; (C) Danish plasma controls. The antigen was: lanes: 1, GST culture before IPTG induc-
tion; 2, GST culture after IPTG induction; 3, rLePa culture before IPTG induction; 4, rLePa culture after IPTG induction. Molecu-
lar mass markers are indicated.
Table 1
Proliferative response using PPD, crude L. donovanii promasti-
gote sonicate (LDS) and rLePa in PBMC from individuals pre-
viously infected with L. donovanii
Antigen Donor
1 2 3 4 5 6 7
PPD 2.6a 10.7 2.3 2.8 14.2 1.7 25.4
LDS 9.2 16.0 3.6 3.5 6.4 0.7 21.7
rLePa 0 2.9 0.2 0.2 1.4 0.1 0.5
Controlb 0 0 0.1 0 0 0 0.3
A positive proliferative response was de¢ned as SIs 2.0 with
increment of s 0.3 kCPM.
aThe incorporation of [3H]thymidine into unstimulated cultures,
which was s 0.4 kCPM for all donors, was subtracted.
bControl antigen was column eluate without rLePa.
Fig. 5. Antibody reactivity (units) in plasma evaluated by ELI-
SA using individual plasma samples from three di¡erent groups.
The groups were endemic controls from the Sudan, visceral
leishmaniasis (VL) patients from the Sudan and cutaneous
leishmaniasis (CL) patients from the Sudan, respectively. The
horizontal line indicates the cuto¡ value.
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were statistically analysed, a signi¢cant di¡erence
(P6 0.01) was found between the two experimental
groups.
The mice were sacri¢ced at week 10 post infection
and the lesions were evaluated for the presence of
parasites, but no di¡erence was found between the
number of parasites in the pcDNA-LePa vaccinated
mice and the controls (data not shown). However,
one of the pcDNA-LePa vaccinated mice had no
visible amastigotes in the lesion and no promasti-
gotes could be grown from the spleen (data not
shown).
4. Discussion
In this study we used antibody-based screening of
a cDNA library to identify a novel Leishmania anti-
gen with similarity to the human 20S proteasome
a-type subunit. The L. donovanii antigen, LePa, is
immunogenic during natural infections in humans
and a LePa DNA vaccine induced an initial reduction
in the lesion size of mice challenged with L. major.
During the initial DNA sequencing of isolated
cDNA clones, several of these clones showed similar-
ity to already known sequences. More than 20% of
all the isolated cDNA clones showed various degrees
of similarity to kinesin-like proteins and heat shock
proteins [4].
DNA sequence analysis and Northern blot analy-
sis indicated that a full length poly(A)mRNA was
isolated, and only one transcript of the expected size
was present. In the Northern blot we used less amas-
tigote poly(A)mRNA than promastigote poly-
(A)mRNA due to the time consuming task of pro-
ducing amastigotes in large amounts. However, a
transcript of similar size was also observed in the
amastigote stage. By aligning the derived amino
acid sequence to human proteasome a-subunit, the
putative Leishmania methionine start codon also
aligned at the start codon of the human homologue,
indicating the isolation of a full length poly-
(A)mRNA.
DNA and protein database search showed that the
translated protein was novel to L. donovanii, but
showing similarity to the human 20S proteasome a-
type subunit and other proteasome homologues. The
a-type subunit is part of the multicatalytic proteinase
complex as described in [25]. In vivo, the 20S protea-
some has been shown to degrade abnormal proteins,
e.g. misfolded proteins induced by heat shock, and
function as a regulatory protein by degrading active
enzymes [28]. Recently, a 20S proteasome was re-
ported isolated from Trypanosoma brucei [29], but
no DNA sequence data were given. Thus, this is
the ¢rst report on isolation and sequencing of a
20S proteasome subunit from Leishmania and trypa-
nosomatid parasites in general.
The immunogenicity of the isolated LePa cDNA
clone was con¢rmed in a Western blot by the reac-
tivity of GST-LePa with the same plasma pool from
visceral leishmaniasis patients as used in the screen-
ing process. In the Western blot analysis, several
antibody reactive bands were visible in the crude
GST-LePa antigen fraction that was incubated with
the human leishmaniasis plasma pool. These bands
are probably breakdown products of the GST-LePa.
Fig. 6. Western blot analysis of antibody reactivity against puri-
¢ed rLePa. Lanes: 1, serum from mice immunized with
pcDNA-LePa; 2, serum from mice immunized with empty
pcDNA. Molecular mass marker is indicated.
Fig. 7. DNA vaccination of Balb/c mice with LePa DNA. Val-
ues represent mean lesion diameter ( þ S.E.M.) for the two
groups (six mice/group) following challenge with L. major pro-
mastigotes.
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That these bands are not contaminating bands is in-
dicated by the lack of bands above the expected mo-
lecular mass of GST-LePa.
rLePa induced proliferation in two of seven
PBMC cultures from patients who had su¡ered
from visceral leishmaniasis, indicating that the do-
nors had expanded T-cell clones recognizing LePa
after exposure to the parasite. The low percentage
of responders might be due to the fact that the anti-
gen was produced in E. coli. In several studies it has
been shown that recombinant E. coli fusion proteins
have been found to be less e¡ective in activating
T-cells than the native molecules or constructs
made in yeast [30^32]. However, the immunogenicity
of LePa during natural infection in humans was also
demonstrated by the fact that antibodies to rLePa
were found in more than 50% of patients with vis-
ceral leishmaniasis caused by L. donovanii. This per-
centage is comparable to the prevalence of anti-gp63
antibodies in patients with visceral leishmaniasis [17].
Four patients with cutaneous leishmaniasis caused
by L. major had antibodies to rLePa indicating that
there is an immunological cross-reactivity between
LePa from L. major and L. donovanii. This notion
is supported by the fact that PCR ampli¢cation of
the open reading frame of LePa from six L. donovanii
isolates and two L. major isolates revealed a single
band of the same molecular mass (data not shown).
A high degree of similarity between the two Leish-
mania species is also to be expected given the simi-
larity between the human protein and LePa, and the
fact that proteasomes play a pivotal role in the me-
tabolism in various higher organisms [28].
The DNA vaccination studies showed a signi¢cant
protective e¡ect in mice receiving the LePa DNA
vaccine. Mice vaccinated with LePa DNA had small-
er lesions than controls during the ¢rst 7 weeks of
the experiment, thereafter lesion sizes were compara-
ble between the two groups. After 10 weeks, the par-
asite loads in the two groups were also comparable.
This suggests that DNA vaccination with LePa DNA
induced immunological memory and that protective
immunological e¡ector mechanisms were activated at
challenge, but they were not su⁄cient to keep the
infection from progressing. Balc/c mice are notori-
ously di⁄cult to protect from L. major infection,
especially when the challenge dose is as high as 106
parasites as used in our study.
In studies by Gurunathan et al. [33], it was shown
that DNA vaccination of Balb/c mice with LACK
DNA and challenged with 105 promastigotes was
able to signi¢cantly decrease the foot pad swelling
as long as week 20 post infection. In addition, the
parasite load in the draining lymph node was re-
duced by a factor of 100. In our studies, however,
we did not see a signi¢cant di¡erence between the
number of parasites in lesions of pcDNA-LePa vac-
cinated mice and controls. In a recent study by
Sjo« lander et al. [34], DNA vaccination with the solu-
ble and membrane bound form of PSA-2 was able to
reduce the lesion size in C3H/He mice. Walker et al.
[35] were able to obtain a 30% protection in Balb/c
mice when vaccinated with the cell surface glycopro-
tein gp63. However, it is important to point out that
caution has to be taken when comparing di¡erent
mouse strains and di¡erent challenge doses.
In conclusion, the vaccination results obtained by
LePa DNA should not exclude LePa as a potential
DNA vaccine candidate. A recent study [36] has
shown that injection of immunostimulatory CpG oli-
gonucleotides in Balb/c mice followed by L. major
challenge was able to shift the initial Th2 response
towards a Th1 response. Although the LePa DNA
vaccine was unable to protect Balb/c mice against a
Leishmania challenge infection, such immunostimula-
tory sequences added together with the DNA vaccine
or incorporated into the plasmid construct could be a
way to induce a protective immune response using
less protective antigens such as LePa. Studies in this
direction are currently underway.
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